NCT01262924View on ClinicalTrials.gov

Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

October 31, 1997

Primary Completion Date

December 31, 1998

Study Completion Date

December 31, 1998

Conditions
Diphteria, Tetanus and Pertussis
Interventions
BIOLOGICAL

GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine

Intramuscular, single dose

BIOLOGICAL

GSK Biologicals' reduced-antigen-content acellular pertussis vaccine

Intramuscular, single dose

BIOLOGICAL

Tedivax-Adult™/ Td-Rix™

Intramuscular, single dose or 2 doses (in the annex phase)

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY